Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.

"CONFLICT OF INTEREST STATEMENT L.M.R. reported receipt of consultancy fees from Bayer. B.P. reported consultant fees for AstraZeneca, Bayer, Boehringer Ingelheim, Brainstorm Medical, Cereno Scientific, G3 Pharmaceuticals, KBP Biosciences, PhaseBio, Proton Intel, Sanofi/Lexicon, Sarfez, scPharmaceuticals, SQ Innovation, Tricida and Vifor/Relypsa; he has stock options for KBP Biosciences, Brainstorm Medical, Cereno Scientific, G3 Pharmaceuticals, Proton Intel, Sarfez, scPharmaceuticals, SQ Innovation, Tricida, Vifor/Relypsa; he also holds a patent for site-specific delivery of eplerenone to the myocardium (US patent #9 931 412) and a provisional patent for histone-acetylation-modulating agents for the treatment and prevention of organ injury (provisional patent US 63/045 784). S.D.A. has received research support from Abbott Vascular and Vifor International, and personal fees from Abbott Vascular, Bayer, Boehringer Ingelheim, BRAHMS, Cardiac Dimensions, Impulse Dynamics, Novartis, Servier and Vifor Pharma. P.R. reported personal fees from Bayer during the conduct of the study; he has received research support and personal fees from AstraZeneca and Novo Nordisk, and personal fees from Astellas, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, Sanofi and Vifor; all fees are given to Steno Diabetes Center Copenhagen. C.P.K. reported that he is a consultant for Abbott, Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, GSK, Rockwell and Vifor. R.P.-F. reported honoraria fees from Akebia, AstraZeneca, Bayer and Boehringer Ingelheim, and investigator-initiated trial support from Fresenius Medical Care. P.P. reported that he is a consultant for Bayer. A.J., A.L. and N.M. are full-time employees of Bayer AG, Germany. M.F.S. is a full-time employee of Bayer AG, Germany. He is also a shareholder in AstraZeneca, Bayer, Eli Lilly and Novo Nordisk. G.L.B. reported research funding, paid to the University of Chicago Medicine, from Bayer during the conduct of the study; he also reported research funding, paid to the University of Chicago Medicine, from Novo Nordisk and Vascular Dynamics; he acted as a consultant and received personal fees from for Alnylam, Merck and Relypsa; he is an editor of the American Journal of Nephrology, Nephrology and Hypertension, and section editor of UpToDate; and is an associate editor of Diabetes Care and Hypertension Research."

"FUNDING This work was supported by Bayer AG, who funded the FIGARO-DKD study and the reported analysis."